CRISPR Therapeutics AG
Last analysed 21 Sep 2026 · Anchored at $57.10
CRISPR Therapeutics offers enough platform upside and balance-sheet resilience for a starter position, but not enough valuation margin for a full allocation at $57.10.
Investment profile
Green team
The case for
CRSP now combines commercial validation from CASGEVY with roughly $2.36B of cash and securities, giving it unusual financing resilience for a clinical-stage biotech. CASGEVY is scaling commercially, while CRSP retains 40% of the collaboration economics with Vertex.
CTX310 is the strongest upside driver. Phase 1a produced 79% mean ANGPTL3 reduction, 48% triglyceride reduction and 53% LDL reduction at the highest dose, with effects sustained through one year and no treatment-related serious adverse events reported. Beyond CTX310, zugo-cel and several earlier programs create additional shots on goal.
Red team
The case against
The current roughly $3.7B to $3.8B enterprise value already assigns meaningful value to assets that remain largely Phase 1/2 or earlier. The analysis estimates only about 10% probability-weighted upside at the current price, which limits the valuation margin despite the convex scenario distribution.
Permanent gene editing carries meaningful safety tail risk, particularly for cardiovascular indications where existing therapies raise the required safety bar. CASGEVY also has a complex treatment pathway, competition is intense, and CRSP continues to face dilution despite its strong liquidity.
valu8 verdict
CRISPR Therapeutics offers enough platform upside and balance-sheet resilience for a starter position, but not enough valuation margin for a full allocation at $57.10. The case wins on commercial validation, substantial net cash, credible CTX310 data and multiple shots on goal, while the market already prices in meaningful early-stage success. The setup becomes materially more attractive below roughly $50 or after strong CTX310 Phase 1b validation.
The debate
- Has CRSP moved beyond being a single-product gene-editing biotech into a credible multi-platform company?
- Can CTX310 reproduce its Phase 1a efficacy and safety profile in Phase 1b?unresolved
- Can zugo-cel deliver efficacy comparable to autologous CAR-T with better scalability and cost?unresolved
- Does CRSP have enough financial runway to fund multiple catalysts without near-term financing dependency?
Asymmetry
| Scenario | Return % | Probability | Condition |
|---|---|---|---|
| Downside blend | -39.6% | 40% | Severe disappointment or bear outcomes: CTX310 disappoints, zugo-cel fails to differentiate, and/or most of the pipeline fails while CASGEVY ramps slowly. |
| Base | +19.1% | 35% | CASGEVY steadily scales and CTX310 validates its Phase 1b profile. |
| Upside blend | +78.6% | 25% | CTX310 becomes a major cardiovascular franchise, autoimmune CAR-T progresses, with the exceptional case adding success across multiple platform assets. |
Downside blend
- Return %
- -39.6%
- Probability
- 40%
- Condition
- Severe disappointment or bear outcomes: CTX310 disappoints, zugo-cel fails to differentiate, and/or most of the pipeline fails while CASGEVY ramps slowly.
Base
- Return %
- +19.1%
- Probability
- 35%
- Condition
- CASGEVY steadily scales and CTX310 validates its Phase 1b profile.
Upside blend
- Return %
- +78.6%
- Probability
- 25%
- Condition
- CTX310 becomes a major cardiovascular franchise, autoimmune CAR-T progresses, with the exceptional case adding success across multiple platform assets.
Green team was right
- CASGEVY provides real commercial validation for CRSP's editing platform.
- CTX310 has produced unusually strong early efficacy with durable lipid reductions.
- The balance sheet provides enough runway for several clinical programs and potential failures.
Red team was right
- Most of the value beyond CASGEVY still depends on immature clinical programs.
- Permanent gene editing carries a demanding safety hurdle, especially in cardiovascular disease.
- At the current enterprise value, meaningful pipeline success is already reflected in the valuation.
Deciding factor
Whether CTX310 Phase 1b confirms durable efficacy and clean safety strongly enough to justify the pipeline value already embedded in the current valuation.
What would change this
- CTX310 Phase 1b confirms roughly 40-50%+ triglyceride and LDL reductions with durable editing, clean liver safety and low patient variability.
- Zugo-cel demonstrates durable drug-free remissions across multiple autoimmune indications with an outpatient-friendly profile.
- CASGEVY adoption stalls despite expanding treatment-center capacity.
- Annual cash burn rises materially above roughly $500-600M without corresponding clinical progress, or equity dilution accelerates.
Key risk
A meaningful safety signal in CTX310 or another in-vivo editing program could permanently impair the most important source of pipeline value.
Not covered
The most material evidence gap is confirmatory CTX310 Phase 1b efficacy and safety, including durability, liver safety and patient-to-patient variability.
Commercial validation and cash runway support upside, but CTX310 still carries the thesis.
About CRISPR Therapeutics AG
CRISPR Therapeutics (CRSP) is a gene editing company built around CRISPR/Cas9. Its first commercial product is Casgevy, an ex vivo edited cell therapy for sickle cell disease and transfusion-dependent beta thalassemia, developed and sold with Vertex. CRISPR takes a minority share of program economics while Vertex leads manufacturing and commercialization. Behind Casgevy sit wholly owned and partnered programs in cardiovascular in vivo editing, allogeneic CAR-T, and other modalities.
CRSP stock is less a pure science platform than a claim on whether gene editing becomes a repeatable commercial franchise. Casgevy proves the modality can reach patients. The economics for CRISPR are still catching up to Vertex-recorded sales, because the cost and profit split leaves CRISPR funding its share until the product turns clearly profitable. Uptake depends on treatment-center capacity, conditioning intensity and how many eligible patients actually start the multi-step process.
The next layer of value is whether the pipeline produces a second and third product without burning the balance sheet. CTX310 aims at one-time lipid risk reduction. Zugo-cel tests off-the-shelf cell therapy in oncology and autoimmune settings. Earlier in vivo and advanced-editing programs add optionality and execution load. Competition includes other CRISPR and gene-editing shops, plus conventional drugs in each disease.
Observers disagree on what CRSP is. Some see the first CRISPR commercial franchise with a deep enough pipeline to matter beyond one Vertex partnership. Others see a company still living mostly on optionality and partnership accounting until Casgevy economics and a second asset prove out. CRISPR Therapeutics remains a gene editing company with one approved product. The platform story only counts if more programs clear the clinic.